Latest news with #tripleNegative
Medscape
24-06-2025
- Health
- Medscape
Metastatic Breast Cancer Highlights From ASCO 2025
An exceptional range of practice-changing advancements in metastatic breast cancer across all subtypes were presented at ASCO 2025 and are discussed by Dr Ann Partridge of the Dana-Farber Cancer Institute. Beginning with HER2-positive disease, Dr Partridge reports on the DESTINY-Breast09 trial investigating whether trastuzumab deruxtecan (T-DXd) + pertuzumab (P) could improve upon results from the standard of care regimen, taxane + trastuzumab + P (THP), in the first-line setting. T-DXd + P increased progression-free survival (PFS), offering a future option for patients with very aggressive disease — although, Dr Partridge notes, several clinical questions remain. She highlights three studies in HER2-negative disease, starting with the SERENA-6 trial in which some patients treated with endocrine therapy who had ESR1 mutation, detected by circulating tumor DNA analysis, were switched to camizestrant. The camizestrant arm demonstrated meaningful PFS improvement. She also notes the first phase 3 trial of a proteolysis-targeting chimera, vepdegestrant, which demonstrated improved PFS in patients with ESR1 mutation. Continuing in the HER2-negative setting, she reports the updated overall survival results for inavolisib that continue to demonstrate positive PFS results. Switching gears to triple-negative disease, she discusses promising results from the ASCENT-04 trial, which tested the antibody-drug conjugate sacituzumab govitecan against chemotherapy.
Medscape
09-06-2025
- Health
- Medscape
ASCO 2025: Key Highlights in Metastatic Breast Cancer
The 2025 ASCO Annual Meeting featured several major advances in metastatic breast cancer, which Heather McArthur, MD, reports on here. In triple-negative disease, the ASCENT-04 trial showed that combining sacituzumab govitecan with pembrolizumab significantly improved progression-free survival, suggesting a new standard for programmed death-ligand 1 (PD-L1)-positive patients. In HER2-positive disease, trastuzumab deruxtecan plus pertuzumab reduced the risk for progression or death vs the CLEOPATRA regimen in the DESTINY-Breast09 study, particularly benefiting hormone receptor-negative patients. Finally, the VERITAC-2 study showed that the oral PROTAC vepdegestrant significantly benefited patients with ESR1-mutated, estrogen receptor (ER)-positive, HER2-negative tumors, adding a promising targeted option to the treatment landscape.
